This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
FibroGen (FGEN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 357.14% and 492.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for FibroGen (FGEN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to FibroGen (FGEN) stock based on the movements in the options market lately.
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 22.06% and 19.32%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss
by Zacks Equity Research
Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.
Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
by Zacks Equity Research
Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.
Options Traders Expect Huge Moves in FibroGen (FGEN) Stock
by Zacks Equity Research
FibroGen (FGEN) needs investors to pay close attention to the stock based on moves in the options market lately.
What's in the Cards for Corbus (CRBP) This Earnings Season?
by Zacks Equity Research
Corbus (CRBP) is expected to provide updates on its pipeline candidates in the fourth quarter conference call.
What's in Store for Teladoc's (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) Q4 earnings might suffer high expenses, partly offset by rise in revenues.
Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Tenet Healthcare's (THC) Q4 earnings are likely to suffer lower admissions due to divestitures.
FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -42.86% and -37.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Cronos (CRON) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Cronos (CRON) reports third-quarter results.
What's in the Cards for BioSpecifics (BSTC) in Q3 Earnings?
by Zacks Equity Research
On BioSpecifics' (BSTC) Q3 conference call, investor focus will be on its progress with the development of CCH for treating uterine fibroids.
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 51.72% and 53.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in FibroGen (FGEN): Stock Soars 48.2%
by Zacks Equity Research
FibroGen (FGEN) was a big mover last session, as the company saw its shares rise over 48% on the day amid huge volumes.
Why Did FibroGen (FGEN) Stock Hit All-Time High Today?
by Benjamin Rains
Shares of FibroGen (FGEN) skyrocketed on Tuesday after the biotech company reported strong results in its most recent series of tests for its new drug that is set to help treat a fatal lung disease.
Should You Buy FibroGen (FGEN) Ahead of Earnings?
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and FibroGen, Inc. (FGEN) may be one such company.
Mylan (MYL) Q1 Earnings: Will the Stock Pull a Surprise?
by Zacks Equity Research
Mylan N.V. (MYL) is scheduled to report first-quarter 2017 results on May 10, before the market opens.
What's in the Cards for Repros (RPRX) this Earnings Season?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let's see how things are shaping up for this quarter.
Should You Sell FibroGen, Inc (FGEN) Before Earnings?
by Zacks Equity Research
FibroGen, Inc (FGEN) stock looks lucrative Before Earnings on the back of its solid zacks rank and positive earnings ESP.
Is Endo (ENDP) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Endo International plc (ENDP) is scheduled to report first-quarter 2017 results on May 9, before the opening bell.
Is Horizon Pharma (HZNP) Poised for a Beat in Q1 Earnings?
by Zacks Equity Research
Horizon Pharma plc (HZNP) is scheduled to report first-quarter 2017 results before the opening bell on May 8.
What's in the Cards for Allergan (AGN) this Earnings Season?
by Zacks Equity Research
Allergan plc (AGN) will be reporting first-quarter 2017 earnings result on May 9, before the market opens.
Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) is expected to report first-quarter 2017 on May 9, after market closes.